SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-024134
Filing Date
2023-07-10
Accepted
2023-07-10 17:16:31
Documents
16
Period of Report
2023-07-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 77213
2 ex10-1.htm EX-10.1 335680
3 ex10-2.htm EX-10.2 327890
4 ex10-3.htm EX-10.3 219656
5 ex10-4.htm EX-10.4 220476
  Complete submission text file 0001493152-23-024134.txt   1604903

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE evfm-20230703.xsd EX-101.SCH 3009
7 XBRL LABEL FILE evfm-20230703_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE evfm-20230703_pre.xml EX-101.PRE 22355
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3235
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 231080582
SIC: 2834 Pharmaceutical Preparations